$PSNL News

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years

BTIG Downgrades Personalis to Neutral

Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis Deal - What's Changed

On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis Reports Second Quarter Results and Recent Highlights

Personalis Q2 EPS $(0.30) Misses $(0.27) Estimate, Sales $22.357M Beat $16.783M Estimate

Tempus makes $1.5B bet to corner cancer-test market

Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion

Personalis, Inc. (PSNL) M&A Call Transcript

Personalis, Inc. (PSNL) Tempus AI, Inc. - M&A Call - Slideshow

Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal

TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers

Tempus AI Bets on MRD Testing Growth With Personalis Acquisition

Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B